| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue, net | - | - | - | 416 |
| Cost of sales | 0 | 0 | - | - |
| Cost of sales - inventory impairment and loss on firm purchase commitments | 0 | 0 | - | 809 |
| Acquired in-process research and development | 0 | - | - | 36,203 |
| Research and development | 19,855 | 27,217 | 22,119 | 21,237 |
| Selling, general and administrative | 16,172 | 15,640 | 15,684 | 17,828 |
| Restructuring expenses | 0 | 0 | - | - |
| Total operating expenses | 36,027 | 42,857 | 37,803 | 76,077 |
| Loss from operations | -36,027 | -42,857 | -37,803 | -75,661 |
| Interest income | 1,821 | 1,960 | 2,231 | 3,098 |
| Other expense, net | -180 | -546 | -335 | -141 |
| Total other income, net | 1,641 | 1,414 | 1,896 | 2,957 |
| Loss before income taxes | -34,386 | -41,443 | -35,907 | -72,704 |
| Provision for income taxes | 0 | 0 | - | - |
| Net loss | -34,386 | -41,443 | -35,907 | -72,704 |
| Earnings per share, basic, total | -0.37 | -0.46 | -0.42 | -1.07 |
| Earnings per share, diluted, total | -0.37 | -0.46 | -0.42 | -1.07 |
| Weighted average number of shares outstanding, basic, total | 93,332,930 | 89,138,568 | 85,697,108 | 68,091,446 |
| Weighted average number of shares outstanding, diluted | 93,332,930 | 89,138,568 | 85,697,108 | 68,091,446 |
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)